Wednesday, October 26

Last day of ASTRO's 64th Annual Meeting! Today’s Daily News features a video message from Andrea Ng, MD, MPH, FASTRO, coverage on Tuesday's programming, including the Keynote II, Awards Ceremony, and expert commentary on abstracts presented at the meeting and previews what's in store for the last day!

Wednesday Digital Daily Access the Digital Daily from day 4 at the 2022 ASTRO Annual Meeting..

Keynote II Yesterday morning, keynote speaker Richard Deming, MD, spoke to a packed room of attendees who were eager to learn about improving patients’ lives. 

Reduced Volume and Dose Results of reduced volume and dose for patients with HPV-positive squamous cell cancers of the oropharynx initially treated with surgical resection. 

Immunotherapy and NSCLC Percy Lee, MD, et al. presented findings from a phase II trial evaluating the safety and efficacy of stereotactic ablative radiotherapy (SABR) in combination with durvalumab for early stage medically inoperable non-small cell lung cancer (NSCLC).

SRT for Prostate Phase II results of SALV-ENZA Trial represent important step forward in optimizing SRT delivery.

FLASH Therapy New studies shine light on FLASH therapy.

SABR for Primary RCC Long-term outcomes of SABR to primary renal cell carcinoma: A multicenter analysis from IROCK (International Radiosurgery Oncology Consortium for Kidney)